Founded in 2015, the company is developing therapies for the top dermatology and skin care conditions – Acne, Atopic Dermatitis (AD), Rosacea, Psoriasis, and Skin Infections, which have a huge impact on patients’ quality of life (~230 million patients suffer from these skin diseases) Our scientific approach is to combine new scientific developments in the dermal microbiome and in the innate immune system to create novel therapies that restore skin homeostasis. Our lead microbiome Phase I/II clinical program addresses the Atopic Dermatitis (AD) market with 15 M US patients (132 M worldwide), is NIH funded, and IP protected with an exclusive license from UCSD. UCSD Dermatology Professor Richard L. Gallo is a world leader in the use of microbes as novel medicines. He is a co-founder and head of MatriSys Bio’s Scientific Advisory Board. His work has focused on host defense and mutualistic interactions with microbes on the skin, with a particular interest in antimicrobial peptides and the basic functions of the skin microbiome. Through high-throughput screening of the normal human skin microbiome, Dr. Gallo’s group has identified specific strains of commensal Staphylococcus species that kill pathogenic bacteria and enhance skin innate immune defense. One of those harmless commensals on human skin, S. hominis Sh-A9 produces lantibiotic peptides that display specific, potent antimicrobial activity towards Staphylococcus aureus, the pathogen associated with Atopic Dermatitis persistence. S. aureus is associated with atopic dermatitis (AD), a chronic inflammatory skin that is complicated by recurrent infections of skin lesions by bacterial, viral, and fungal pathogens. Importantly, unlike antibiotics, Sh-A9 does not affect other skin commensal bacteria, leading to the natural rebalance of the skin microbiome. This approach is a dramatic improvement over broad-spectrum antibiotics that kill pathogenic bacteria but also destroy the beneficial bacteria by friendly fire.

MatriSys Bioscience, Inc. is the most clinically advanced skin microbiome company. Founded in 2015, the company is developing therapies for the top dermatology and skin care conditions – Acne, Atopic Dermatitis (AD), Rosacea, Psoriasis, and Skin Infections Its scientific approach is to combine new scientific developments in the dermal microbiome and in the innate immune system to create novel therapies that restore skin homeostasis. UCSD Dermatology Professor Richard Gallo is a world leader in the use of microbes as novel medicines. He is a co-founder and head of MatriSys Bio’s Scientific Advisory Board. His work has focused on host defense and mutualistic interactions with microbes on the skin. Through high-throughput screening of the normal human skin microbiome, Dr. Gallo’s group has identified specific strains of commensal Staphylococcus species that kill pathogenic bacteria and enhance skin innate immune defense. One of those common and harmless commensals on human skin, S. hominis Sh-A9 produces lantibiotic peptides that display specific, potent antimicrobial activity towards Staphylococcus aureus, the pathogen associated with Atopic Dermatitis persistence. Our lead microbiome Phase I/II clinical program addresses the AD market with 15 M US patients (132 M worldwide), is NIH funded, and IP protected with an exclusive license from UCSD. Sh-A9 is selective and highly potent against Staphylococcus aureus, which is associated with AD, a chronic inflammatory skin that is complicated by recurrent infections of skin lesions by bacterial, viral, and fungal pathogens. Importantly, unlike antibiotics, our S. hominis Sh-A9 does not affect other skin bacteria, leading to the natural rebalance of the skin microbiome.AD is not curable. It affects 230 million people globally (about 10-20 % of infants and 3.5% of adults, and is treated with topically applied steroids and/or topical antibiotic therapies which kill the other commensal bacteria by friendly fire.

Anti-breast and ovary-cell surface antigen 1 for the treatment of ovarian cancer• Demonstrated over-expression in a vast majority of ovarian cancer. The antigen is also strongly expressed in breast cancer. • Characterized specific monoclonal antibodies and uptake and intracellular accumulation in neoplatic cells expressing the antigen with minimum/no uptake by normal cells. Anti-TESTISIN for the treatment of ovarian cancer• Demonstrated overexpression in ovarian cancer. Anti-testisin MAbs accumulate within the endolysosome compartment in testisin-expressing cells, making it possible to design armed antibodies for added therapeutic efficacy.Anti-TMPRSS4 for the treatment of ovarian and pancreatic cancer• Demonstrated upregulation in ovarian and pancreatic cancer. Specific MAbs are internalized. tasks of various departments from early gene discovery and bioinformatics to in vitro pharmacology and in vivo safety studies. Planned, designed development plans, determined timelines and executed programs to identify, characterize and validate novel tumor targets for potential therapeutic intervention.Supervised a team of scientists focused on the development of therapeutic antibodies to novel tumor antigens.Devised strategies to address mechanisms of action and toxicity in neoplastic diseases. Carried out histopathology characterization of antibody leads in normal and diseased human tissues. Supervised early stage pharmacological characterization of lead therapeutic antibodies. Developed program for arming therapeutic antibodies to increase antibody-targeted immunotherapy.Designed and coordinated in vivo studies & preclinical studies for evaluation of efficacy in animal tumor models.Identified which studies or aspects of development program to be outsourced to contract research organizations and projected timelines for initiation, completion and review of studies

Managed Ph.D. scientists and research associates involved in the discovery and development of candidate molecules, including Mabs, cytokines and growth factors..Determined the mechanisms of action and mechanisms of toxicity of lead molecules.Identified organ, tissue and cellular distribution of novel tumor antigens.Identified organ, tissue and cellular distribution of novel biotherapeutics.Developed and tested drug delivery systems.Supported animal model development, including human xenograft/nude mouse models. Established new technologies, assays and instrumentation to support drug discovery and development, in particular developed semi-quantitative methodologies to screen for binding, uptake of pharmaceutical entities in organs, tissues and internalization in cells. Analyzed data for internal and external presentations. Wrote communications for peer-reviewed Journals. Wrote and/or supervised the writing of internal reports and portions of regulatory documents.Developed and tested drug delivery systems.Reviewed business development proposals to facilitate business decision.Participated in project team management for anti-HER2Mabs, anti-Vascular Endothelium Growth Factor MAbs, anti-Prostate Stem Cell Antigen MAbs, and Xolair. Reviewer and Member of Board of Editors for diverse Scientific Journals.